Large pharma runs hundreds of trials. Recruitment is scaled. Operations are mature.Yet completion remains difficult to predict across the portfolio, even as enrollment improves.The missing operational layer is patient readiness. Jumo Health adds it.
Large pharmaceutical companies have optimized recruitment at a level most of the industry cannot match. Site networks are broad. Vendor ecosystems are sophisticated. Data infrastructure is real. And yet familiar patterns persist across programs: screen failure rates that plateau study over study, rescue recruitment that becomes a standing budget line, site burden that accumulates across protocols, and completion rates that stay flat despite better technology and larger databases.
The investment in trial infrastructure has been substantial and effective. The one dimension it has not yet reached is the one that determines whether patients complete: readiness.
When readiness governance operates at the portfolio level, patterns emerge that individual trial management cannot surface. PRISM identifies which readiness failures are protocol-specific and which are systemic across programs, enabling upstream fixes that improve outcomes across every active study simultaneously.
Readiness Intelligence surfaces friction patterns that repeat across trials, therapeutic areas, and geographies. Instead of treating every screen failure as an isolated event, PRISM identifies systemic readiness gaps and enables upstream fixes that prevent the same failures from recurring across the portfolio.
One partner governing readiness across education (CORE) and operations (PRISM) instead of fragmenting the patient experience across agencies, CROs, and point solutions. A single readiness layer replaces the patchwork of disconnected engagement vendors that currently operate without shared intelligence.
Three live indices provide real-time visibility into trial health across the portfolio. The Patient Experience Composite Index (PXCI), Informed Engagement Quality Score (IEQS), and Composite Recruitment Index (CRI) replace retrospective reports with continuous readiness measurement.
MSA-based relationship with standardized SOWs across programs. No per-study procurement cycles. No fragmented vendor contracts. Each study deploys in 6-8 weeks with a repeatable onboarding process your operations team will recognize.
Every portfolio has different readiness gaps. Some need better patient education. Some need operational governance. Most need both. Choose the entry point that matches your current challenge.
These are not projections. These are measured outcomes across 300+ studies, 72,000+ patients, and 270+ conditions.
Jumo Health operates as a readiness governance layer that sits alongside your CRO, not in place of it. CROs manage trial operations and site management. Jumo Health governs the patient readiness dimension that CROs are not structured to address. PRISM integrates with existing workflows, and CORE educational content deploys through existing site infrastructure. Most enterprise clients run Jumo Health in parallel with their CRO partners without any workflow disruption.
Yes. PRISM is built for enterprise integration. The system connects with EDC platforms, CTMS, IRT/RTSM, eConsent tools, and patient-facing portals through standard APIs and data feeds. Integration scope is defined during onboarding and typically completed within the 6-8 week deployment window. PRISM does not replace your existing systems. It adds the readiness intelligence layer that those systems were not designed to provide.
Enterprise engagements are structured under a Master Service Agreement (MSA) with standardized Statements of Work (SOWs) per study. Portfolio pricing provides cost predictability across programs and eliminates per-study procurement cycles. Volume-based structures are available for organizations running multiple concurrent studies. Your procurement team will have a single contract governing all programs rather than fragmented vendor agreements.
Enterprise evaluation typically spans 4-8 weeks and includes a portfolio assessment, readiness diagnostics on a pilot study, and integration planning. Once contracted, each study deploys in 6-8 weeks. Many enterprise clients begin with a single study to validate outcomes, then expand across the portfolio. The three PRISM diagnostics (Baseline TRI, Readiness Friction Map, Readiness Execution Blueprint) are delivered during the evaluation phase so your team can assess value before full commitment.
Jumo Health has supported studies across 72 languages and 270+ conditions, with deep experience navigating IRB and ethics committee requirements across global geographies. All CORE educational content is developed to regulatory standards and reviewed for clinical accuracy. PRISM operates within existing regulatory frameworks and does not introduce new consent requirements. The team manages the regulatory submission process for educational materials as part of the standard deployment workflow.
Across 300+ studies, Jumo Health has delivered a 56% decrease in screen failure rates, a 64% decrease in time to last patient in, and a 96% increase in study completion rates. At the portfolio level, clients typically see reduced rescue recruitment spend, lower cost per completer, compressed enrollment timelines, and improved site satisfaction scores. Three live indices (PXCI, IEQS, CRI) provide real-time visibility into these metrics across every active study.
In two days, you get three execution diagnostics on your program.
How likely each eligible patient cluster is to activate, persist, and complete, before any intervention.
The barriers most likely to suppress activation, enrollment, and completion in each cluster, and how to mitigate them.
Which clusters to target, which barriers to address, which interventions to deploy, and what completion lift to expect.